Original scientific paper
Serum C-reactive protein to albumin ratio as a novel inflammation biomarker in psoriasis patients treated with adalimumab, ustekinumab, infliximab, and secukinumab: a retrospective study
Funda Tamer
; Department of Dermatology, Gazi University School of Medicine, Ankara, Turkey
Emine Avcı
; Department of Infectious Diseases, General Directorate of Public Health, Ankara, Turkey
Abstract
Aim To assess C-reactive protein to albumin ratio (CAR) before and after treatment with biological agents in patients
with psoriasis to determine whether CAR can be used as
an inflammation biomarker.
Methods Medical records of patients with psoriasis treated with biological agents at the Department of Dermatology, Gazi University Hospital were retrospectively evaluated
between June 2018 and August 2019. The patients were
divided into four groups based on the type of treatment
(adalimumab, ustekinumab, infliximab, secukinumab). CAR
was evaluated before and three months after treatment.
Results The study enrolled 157 patients with psoriasis vulgaris (91 male) aged between 18 and 85. CAR significantly decreased in all treatment groups (adalimumab group
P<0.001; ustekinumab P=0.006; infliximab P=0.007;
secukinumab P<0.001). The most prominent decrease in
CAR was observed in patients treated with secukinumab
(median CAR before treatment 1.52 [1.01-3.04] and after
treatment 0.84 [0.62-0.99]).
Conclusion CAR may be a good indicator of systemic inflammation in psoriasis patients treated with biological
agents
Keywords
Hrčak ID:
274617
URI
Publication date:
31.8.2020.
Visits: 608 *